A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease.

导出 LinkOut

翻译打印收藏纠错

作者： Dolores,Grosso ^[1] ; Sameh,Gaballa ^[2] ; Onder,Alpdogan ^[2] ; Matthew,Carabasi ^[2] ; Joanne,Filicko-O'Hara ^[2] ; Margaret,Kasner ^[2] ; Ubaldo,Martinez-Outschoorn ^[2] ; John L,Wagner ^[2] ; William,O'Hara ^[3] ; Shannon,Rudolph ^[2] ; Inna,Chervoneva ^[4] ; Beth,Colombe ^[5] ; Patricia Cornett,Farley ^[6] ; Phyllis,Flomenberg ^[7] ; Barbara,Pro ^[2] ; Manish,Sharma ^[2] ; Wenyin,Shi ^[8] ; Mark,Weiss ^[2] ; Neal,Flomenberg ^[2]

作者单位： Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: dolores.grosso@jefferson.edu. ^[1] Department of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. ^[2] Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. ^[3] Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania. ^[4] Tissue Typing Laboratory, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. ^[5] Clinical Laboratory for Cellular Therapy, Thomas Jefferson Hospital, Philadelphia, Pennsylvania. ^[6] Department of Infectious Diseases, Thomas Jefferson University, Philadelphia, Pennsylvania. ^[7] Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania. ^[8]

关键词 Disease-free survival Donor availability Haploidentical stem cell transplantation Nonrelapse mortality T cell dosing